MedTrace Logo

A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD

NCT06309277 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-05-08

Study results available
· View outcomes & findings →

Summary

The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy.

Conditions

Interventions

DRUG

GM-1020

N-methyl-D-aspartate (NMDA) receptor antagonist

Sponsors & Collaborators

  • Gilgamesh Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Gerard Marek, MD · Gilgamesh Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2025-03-04
Completion
2025-03-27

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06309277 on ClinicalTrials.gov